研究目的
Investigating the therapeutic effects of a novel organoiridium-albumin bioconjugate on cancer cells through photodynamic therapy.
研究成果
The organoiridium-albumin bioconjugate (Ir1-HSA) exhibits enhanced phosphorescence, long phosphorescence lifetime, and high 1O2 generation quantum yield, making it a potent photosensitizer for photodynamic therapy. It selectively targets cancer cells and shows significant photocytotoxicity while remaining non-toxic to normal cells.
研究不足
The study focuses on in vitro experiments and the specific mechanism of nuclear targeting by Ir1-HSA requires further investigation.
1：Experimental Design and Method Selection:
Synthesis of a novel organoiridium-albumin bioconjugate (Ir1-HSA) via reaction of a pendant maleimide ligand with human serum albumin.
2：Sample Selection and Data Sources:
Human cancer cell lines (lung: A549; hepatoma: Hep-G2; cisplatin resistant lung: A549R) and normal human cells (lung: MRC-5; liver: LO2).
3：2). List of Experimental Equipment and Materials:
3. List of Experimental Equipment and Materials: Confocal microscopy, RP-HPLC, EPR spectroscopy, CellTiter-Glo? 3D Cell Viability Assay.
4：Experimental Procedures and Operational Workflow:
Incubation of cells with Ir1 or Ir1-HSA, irradiation with blue LEDs, measurement of phosphorescence and 1O2 generation.
5：Data Analysis Methods:
Determination of IC50 values, phosphorescence quantum yield, and 1O2 quantum yield.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
